Latest News
TG Therapeutics, Inc.
- TG Therapeutics reports phase 1 MS trial results for azer-cel
- TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
- TG Therapeutics (TGTX) Showcases Long-Term MS Trial Data and Adv
- TG Therapeutics reports seven-year BRIUMVI disability and safety findings
- TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
- TG Therapeutics (NASDAQ:TGTX) Pairs Strong Growth With a High-Quality Breakout Setup
- TG Therapeutics publishes five-year Briumvi comparison study
- TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
- TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
- TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in Biotech
- Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
- Investigation launched into TG Therapeutics' of...
Headlines from the last 30 days, linking to the original publishers. See all market news →